Substance / Medication

Stavudine

Overview

Active Ingredient
stavudine
RxNorm CUI
59763

Indications

Clinical Studies (14) [see] Stavudine capsules, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV)-1 infection.

Labeler: State of Florida DOH Central PharmacyUpdated: 2013-09-30T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Warnings and Precautions (5.1) [see] Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine and other antiretrovirals. Fatal lactic acidosis has been reported in pregnant wome

Contraindications

When this intervention should not be used

Stavudine capsules are contraindicated in patients with clinically significant hypersensitivity to stavudine or to any of the components contained in the formulation.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Low dose versus high dose stavudine for treating people with HIV infection.
Magula Nombulelo, Dedicoat Martin · Cochrane Database Syst Rev · 2015
PMID: 25627012Meta-AnalysisFull text (PMC)
Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding Alicen, Rutherford George W, Siegfried Nandi · Cochrane Database Syst Rev · 2010
PMID: 20687097Meta-Analysis
Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.
Hill Andrew, Ruxrungtham Kiat, Hanvanich Mattana et al. · Expert Opin Pharmacother · 2007
PMID: 17376022Meta-Analysis
Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
Siegfried N L, Van Deventer P J U, Mahomed F A et al. · Cochrane Database Syst Rev · 2006
PMID: 16625606Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Stavudine (substance)
SNOMED CT
386895008
UMLS CUI
C0164662
RxNorm CUI
59763
Labeler
State of Florida DOH Central Pharmacy

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.